( en | de | ru )

 

Disambiguation of "Lambris, John D."

Author of the publication

copydeleteadd this publication to your clipboard
Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.

, , and . Molecular Immunology, 39 (10): 557--566 (January 2003)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

John D Howgate

D Böttger

D Zeppenfeld

D Zumkeller

D Bruß

 

Other publications of authors with the same name

Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm., , , , , , , , and . Circulation, 119 (13): 1805--1813 (April 2009)Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches., , , , and . Adv.Exp.Med.Biol., (2015)Absence of Mannose-Binding Lectin Prevents Hyperglycemic Cardiovascular Complications, , , , , and . American Journal of Pathology, 180 (1): 104--112 (2012)Illuminating the latest advances in innate immunity on the island of the sun god., and . Expert review of clinical immunology, page 875--878. University of Louisville, Oral Health and Systemic Disease, Louisville, KY, USA., (November 2010)Complement in immune and inflammatory disorders: therapeutic interventions., and . Journal of immunology (Baltimore, Md. : 1950), 190 (8): 3839--3847 (April 2013)Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles., , , , , , , , and . 35 (11): 3688--3696 (April 2014)Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3., , and . Molecular Immunology, 39 (10): 557--566 (January 2003)Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia., , , , , , and . Clinical immunology (Orlando, Fla.), (October 2016)A structural basis for complement inhibition by Staphylococcus aureus., , , , , and . Nature Immunology, 8 (4): 430--437 (April 2007)Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation., , , , , , , , , and 2 other author(s). Blood, 129 (8): 970--980 (February 2017)